Examples include p-VAC-seq [26], which integrates tumor mutation and expression data and automates multiple antigen screening steps; PSSMHCpan [27], which can effectively predict the affinity of peptide binding to HLA class I alleles; DBTpred [28], which focuses on single amino acid residue mutations resulting in altered peptide-MHC binding affinity; and RBM-MHC [29], which improved predictions for rare alleles. This evidence concerns the gene HLA-C and neoplasm.